Implandata Ophthalmic Products GmbH | Top MedTech Solution Company in Europe 2018

MedTech Outlook Magazine

Implandata Ophthalmic Products GmbH
Game-changing Treatment Approach for Glaucoma

Advancements in telemedicine and patient monitoring technologies have bridged the gap between physicians and patients, and have enabled care delivery beyond the walls of healthcare institutes. Unfortunately, these technologies are yet to catch up in several specialties. Take ophthalmology for instance; dreaded, chronic conditions such as glaucoma demand continuous monitoring of the eye’s intraocular pressure (IOP): a sensitive parameter which is key and decisional in treating the disease. Unfortunately, ophthalmologists have been under-equipped to keep an eye out for the vision of their patients; until the advent of EYEMATE, a revolutionary eye-monitoring device by Germany based Implandata Ophthalmic Products.

“With our disruptive EYEMATE system, we are at the forefront of modern glaucoma care by combining proprietary sensing technology with IoT and analytics backed digital health solutions. The EYEMATE system enables ophthalmologists to provide better care to their patients,” says Max G. Ostermeier, CEO of Implandata.

Through years of extensive R&D, the company has mastered the art of developing miniaturized implants capable of non-invasively detecting ‘subtle pressure variations’ on one of the most sensitive human organs. Implandata thus fosters a massive leap of advancement in the world of teleophthalmology.

Glaucoma, wherein elevated IOP causes irreversible vision loss by permanently damaging the optic nerve, can only be kept on check by reducing and controlling IOP levels. Although there are numerous therapeutic options to control IOP, patients respond differently to them and a therapy response can quickly change over time. Current methods to measure IOP only allow infrequent in-office measurements and do not provide any information about habitual IOP or even IOP monitoring.The constant threat to lose vision or go blind, because of glaucoma, puts a lot of emotional burden on patients and their families; this is further aggravated by the fact that patients have very limited information about their IOP. Glaucoma is also called the ‘silent thief of sight’ as elevated IOP causing vision loss is typically asymptomatic.

Implandata’s EYEMATE system provides IOP data under normal life conditions at a previously unattainable quality and quantity and provides actionable information via digital solutions to an ophthalmologist.

We are at the forefront of modern glaucoma care by combining proprietary sensing technology with IoT and analytics backed digital health solutions


EYEMATE’s implant, which sizes up to less than the diameter of a ten-cent coin, can be easily implanted without any intervention of the patient’s daily routines. By accessing the implant’s data on EYEMATE’s cloud platform, eye doctors remain informed about their patient’s therapy progress which allows them to proactively titrate and optimize their therapy. Furthermore, with the options to self-monitor their data through a smart-phone app, the patients are also motivated to be involved and adhere to their therapy. “We are extremely pleased that all the patients who have attained our product so far are very satisfied and happy with it. We have not had any reports of safety issues with our product. All our devices are working properly for years and providing useful information, which is really important for a product targeting chronically ill patients,” says Ostermeier with pride.
Evidently, EYEMATE’s immense value proposition has received great appreciation from the medical community. The company has support and considerable investment from eye doctors. Also, several patients and patient organizations have backed the company at multiple levels.

Implandata is currently rolling out its EYEMATE system to ophthalmologists in Germany, Switzerland, and Austria, and will expand further into European countries in 2019. From 2020 onwards, the company plans to start market activities in certain Asian regions, keeping an eye on the Chinese market. They are also preparing a first US IDE study, forecasting an FDA PMA approval in a few years.

Top 20 MedTech Solution Companies in Europe - 2018

Company
Implandata Ophthalmic Products GmbH

Management
Max G. Ostermeier, Founder & CEO

Description
The company’s EYEMATE system provides intraocular pressure, IOP, and data under normal life conditions at a previously unattainable quality and quantity

Implandata Ophthalmic Products GmbH News

Implandata Announces Appointment of New Members Dr. Adrienne Graves and Jan Willem de Cler to Join Board of Directors

HANNOVER, Germany and SAN DIEGO, USA, -- Implandata Ophthalmic Products, an emerging ophthalmic health tech company based in Germany and USA, announced that Dr. Adrienne Graves and Mr. Jan Willem de Cler are appointed as new members of the company's Board of Directors. Jan Willem de Cler will also take over responsibility as Chairman of the Board.
HANNOVER, Germany, Oct. 24, 2023 /PRNewswire-PRWeb/ -- A visual scientist by training and a global industry leader in ophthalmology, Dr. Adrienne Graves brings extensive experience to Implandata. As the former CEO of Santen Inc., she successfully established a strong global presence, bringing multiple ophthalmic products through development to approval and commercialization and leading global teams through successful acquisitions and partnerships. Prior to Santen, she spent 9 years at Alcon, joining as Senior Scientist to establish Alcon's first Retinal Electrophysiology Laboratory. She progressed through roles of increasing responsibility in research and development, including directing clinical development in multiple therapeutic areas and serving as Director of International Ophthalmology. Dr. Graves currently serves as a director on the boards of various ophthalmic pharmaceutical and health-tech companies. She serves on the Foundation Boards of the American Society of Cataract and Refractive Surgery (ASCRS) Foundation, Glaucoma Research Foundation, American Academy of Ophthalmology Foundation (Emeritus), Retina Global, Himalayan Cataract Project, Foundation Fighting Blindness (FFB) and the RD (Retinal Degeneration) Fund. Dr. Graves also co-founded Glaucoma 360 and OWL (Ophthalmic World Leaders, formerly Ophthalmic Women Leaders).
Jan Willem de Cler, was Member of the DAX listed Carl Zeiss Meditec AG Management Board until September 2022, after which he became Executive in Residence and Senior Advisor to Private Equity and Non-Executive Director. Jan Willem studied Business Administration at Nijenrode University in the Netherlands and the University of Oregon, USA where he accomplished his MBA. Jan Willem then started his career at General Electric's FMP and Corporate Audit Staff and spent the next 25 years in Health Care. He held different management positions at GE Medical Systems and became co-founder and Head of Sales and Marketing for GHX - Global Healthcare Exchange Europe, a successful startup that provides B2B solutions for supply chain efficiency between healthcare providers and suppliers. Jan Willem joined ZEISS Group in 2004 as Managing Director for the Benelux, and the French sales and service companies for all divisions, as well as serving as the President of France Chirurgie Instrumentation (FCI). From 2010 he led the Surgical Ophthalmology SBU at Carl Zeiss Meditec AG and built it up to its global leadership position. In 2018 he was appointed to the Board of Carl Zeiss Meditec AG as COO/CHRO/CSO and led M&A.
Implandata Ophthalmic Products, is an ophthalmic health-tech company dedicated to improving the lives of millions of people with glaucoma. Breakthroughs in bio-sensing, telemetry and data analytics led to the EYEMATE system. The CE-marked EYEMATE system is in use at leading eye centers in Europe. In the US market, EYEMATE has obtained the FDA "Breakthrough Device Designation" and IDE studies are in preparation.